{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:05Z","timestamp":1787614805416,"version":"build-2736575974"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":176,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) prevalence is nearing 50% of all heart failure cases and is often associated with advanced age, obesity, atrial fibrillation and hypertension, and medical approaches are limited. This review aims to determine the potential of medical devices or surgical interventions in treating HFpEF and to propose specific phenotypes of HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>A systematic review was conducted using various clinical trial databases and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines followed by descriptive analysis and methodology quality assessment. Inclusion criteria included a medical device or surgical intervention involving HFpEF patients defined by a left ventricular ejection fraction (LVEF) \u226550% and signs of diastolic dysfunction. Twenty-four novel trials were identified involving n = 1752 participants: 17 medical device trials [3 interatrial shunt device trials (n = 1069), 1 atrial flow regulator trial (n = 41), 3 vagal nerve stimulation trials (n = 112), 1 baroreflex activation therapy trial (n = 21), 1 cardiac contractility modulator trial (n = 47), 6 cardiac resynchronization therapy trials (n = 178) and 2 functional electrical stimulation therapy trials (n = 89)] and 7 surgical intervention trials [1 renal denervation trial (n = 25), 3 greater splanchnic nerve ablation trials (n = 111), 2 catheter ablation trials (n = 55) and 1 pericardiotomy procedure trial (n = 4)]. One trial completed phase 3 trials, 20 trials completed phase 1 trials with further trials, and 5 trials completed phase 1 trials without further trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, 16 out of 24 trials have at least demonstrated safety and feasibility. However, despite many trials of a medical device or surgical procedure showing proof of concept to treat HFpEF phenotypes, they do not provide sufficient evidence of long-term benefit. More robust and phenotype-based clinical trials are needed to ensure evidence-based solutions are developed in HFpEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15401","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:55:33Z","timestamp":1756212933000},"page":"3878-3898","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phenotype Characterization of Heart Failure with Preserved Ejection Fraction in Medical Device and Surgical Trials"],"prefix":"10.1093","volume":"12","author":[{"given":"Kurdo","family":"Araz","sequence":"first","affiliation":[{"name":"School of Medicine, RCSI University of Medicine and Health Sciences , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fioretti","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ladak","sequence":"additional","affiliation":[{"name":"School of Medicine, RCSI University of Medicine and Health Sciences , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Obaidan","sequence":"additional","affiliation":[{"name":"UCD School of Medicine, UCD Health Sciences Centre, University College Dublin , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]},{"name":"University of Mississippi , Jackson, Mississippi ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-6185","authenticated-orcid":false,"given":"Aamir","family":"Hameed","sequence":"additional","affiliation":[{"name":"Tissue Engineering Research Group (TERG), Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences , Dublin ,","place":["Ireland"]},{"name":"Trinity Centre for Biomedical Engineering (TCBE), Trinity College Dublin (TCD) , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"2026021804194524000_ehf215401-bib-0001","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0002","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804194524000_ehf215401-bib-0003","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC Scientific Expert Panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0004","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021804194524000_ehf215401-bib-0005","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026021804194524000_ehf215401-bib-0006","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: From mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021804194524000_ehf215401-bib-0007","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ejhf.111","article-title":"Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure","volume":"16","author":"S\u00f8ndergaard","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0008","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijcard.2015.03.198","article-title":"Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant","volume":"187","author":"Malek","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0009","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.cardfail.2015.05.008","article-title":"Rationale and design of the reduce elevated left atrial pressure in patients with heart failure (Reduce LAP-HF) trial","volume":"21","author":"Hasenfuss","year":"2015","journal-title":"J Card Fail"},{"key":"2026021804194524000_ehf215401-bib-0010","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","article-title":"A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): A multicentre, open-label, single-arm, phase 1 trial","volume":"387","author":"Hasenfu\u00df","year":"2016","journal-title":"Lancet"},{"key":"2026021804194524000_ehf215401-bib-0011","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003025","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure: Rationale and design of the randomized trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I)","volume":"9","author":"Feldman","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0012","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","article-title":"Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial","volume":"137","author":"Feldman","year":"2018","journal-title":"Circulation"},{"key":"2026021804194524000_ehf215401-bib-0013","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","article-title":"One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: A randomized clinical trial","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0014","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.jacc.2019.08.1062","article-title":"Effects of interatrial shunt on pulmonary vascular function in heart failure with preserved ejection fraction","volume":"74","author":"Obokata","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0015","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jchf.2023.01.024","article-title":"No-implant interatrial shunt for HFpEF: 6-month outcomes from multicenter pilot feasibility studies","volume":"11","author":"Udelson","year":"2023","journal-title":"J Am Coll Cardiol HF"},{"key":"2026021804194524000_ehf215401-bib-0016","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0735-1097(23)01258-5","article-title":"No-implant interatrial shunting for heart failure with preserved and mildly reduced ejection fraction: 1-month outcomes and updated study design","volume":"81","author":"Fudim","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0017","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3215","article-title":"Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial","author":"Rod\u00e9s-Cabau","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0018","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.1060","article-title":"The PRELIEVE trial: Final 1-year outcomes of the prospective atrial flow regulator study","volume":"44","author":"Paitazoglou","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804194524000_ehf215401-bib-0019","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ehf2.12241","article-title":"Autonomic regulation therapy to enhance myocardial function in heart failure patients: The ANTHEM-HFpEF study","volume":"5","author":"DiCarlo","year":"2018","journal-title":"ESC Heart Failure"},{"key":"2026021804194524000_ehf215401-bib-0020","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2023.03.030","article-title":"Autonomic regulation therapy in chronic heart failure with preserved\/mildly reduced ejection fraction: ANTHEM-HFpEF study results","volume":"381","author":"Kumar","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0021","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12265-018-9853-6","article-title":"Autonomic neuromodulation acutely ameliorates left ventricular strain in humans","volume":"12","author":"Tran","year":"2019","journal-title":"J Cardiovasc Transl Res"},{"key":"2026021804194524000_ehf215401-bib-0022","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023582","article-title":"Neuromodulation of inflammation to treat heart failure with preserved ejection fraction: A pilot randomized clinical trial","volume":"11","author":"Stavrakis","year":"2022","journal-title":"JAHA"},{"key":"2026021804194524000_ehf215401-bib-0023","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.cardfail.2009.06.191","article-title":"Improved functional capacity and cardiovascular structure after Baroreflex Activation Therapy\u2122 in resistant hypertension patients with symptomatic heart failure: Results from European and United States trials of the Rheos\u00ae system","volume":"15","author":"Bisognano","year":"2009","journal-title":"J Card Fail"},{"key":"2026021804194524000_ehf215401-bib-0024","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1002\/ejhf.2619","article-title":"Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: A pilot study (Ccm-HfpEf)","volume":"24","author":"Linde","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0025","volume-title":"Heart failure with preserved ejection fraction treated by cardiac resynchronisation therapy versus rate responsive pacing: A mechanistic study","author":"Lodge","year":"2023"},{"key":"2026021804194524000_ehf215401-bib-0026","volume-title":"REmodeling the Left Ventricle With Atrial Modulated Pacing","author":"Medtronic Cardiac Rhythm and Heart Failure","year":"2021"},{"key":"2026021804194524000_ehf215401-bib-0027","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2023.0675","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: The RAPID-HF randomized clinical trial","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"},{"key":"2026021804194524000_ehf215401-bib-0028","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.hroo.2021.11.015","article-title":"Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the myPACE randomized controlled trial","volume":"3","author":"Infeld","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"2026021804194524000_ehf215401-bib-0029","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: The myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0030","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.hroo.2023.12.001","article-title":"Rationale and design of the PACE HFpEF trial: Physiologic accelerated pacing as a holistic treatment of heart failure with preserved ejection fraction","volume":"5","author":"Habel","year":"2024","journal-title":"Heart Rhythm O2"},{"key":"2026021804194524000_ehf215401-bib-0031","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.hrthm.2024.03.1230","article-title":"PO-04-041 Physiologic accelerated pacing as a treatment for heart failure with preserved ejection fraction","volume":"21","author":"Habel","year":"2024","journal-title":"Heart Rhythm"},{"key":"2026021804194524000_ehf215401-bib-0032","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/eurjhf\/hfs150","article-title":"Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: A pilot study prior to a national clinical research programme","volume":"15","author":"Laurent","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0033","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10741-010-9171-9","article-title":"Functional electrical stimulation of lower limbs in patients with chronic heart failure","volume":"15","author":"Karavidas","year":"2010","journal-title":"Heart Fail Rev"},{"key":"2026021804194524000_ehf215401-bib-0034","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.ahj.2013.06.021","article-title":"Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction","volume":"166","author":"Karavidas","year":"2013","journal-title":"Am Heart J"},{"key":"2026021804194524000_ehf215401-bib-0035","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.rec.2018.01.010","article-title":"Inspiratory muscle training and functional electrical stimulation for treatment of heart failure with preserved ejection fraction: The TRAINING-HF trial","volume":"72","author":"Palau","year":"2019","journal-title":"Rev Esp Cardiol (English Edition)"},{"key":"2026021804194524000_ehf215401-bib-0036","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ejhf.502","article-title":"Renal denervation in heart failure with preserved ejection fraction (Rdt-Pef): A randomized controlled trial","volume":"18","author":"Patel","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0037","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/ejhf.2209","article-title":"Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: First-in-human clinical trial","volume":"23","author":"M\u00e1lek","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0038","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jchf.2022.05.009","article-title":"Transvenous right greater splanchnic nerve ablation in heart failure and preserved ejection fraction: First-in-human study","volume":"10","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol HF"},{"key":"2026021804194524000_ehf215401-bib-0039","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/ejhf.2559","article-title":"Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: Early results of the Rebalance-Hf trial roll-in cohort","volume":"24","author":"Fudim","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0040","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cardfail.2023.12.010","article-title":"Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: Rationale, design and lead-in phase results of the REBALANCE-HF trial","volume":"30","author":"Fudim","year":"2024","journal-title":"J Card Fail"},{"key":"2026021804194524000_ehf215401-bib-0041","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jamacardio.2024.2612","article-title":"Endovascular ablation of the greater splanchnic nerve in heart failure with preserved ejection fraction: The REBALANCE-HF randomized clinical trial","volume":"9","author":"Fudim","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0042","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jchf.2023.01.008","article-title":"Atrial fibrillation ablation for heart failure with preserved ejection fraction","volume":"11","author":"Chieng","year":"2023","journal-title":"J Am Coll Cardiol HF"},{"key":"2026021804194524000_ehf215401-bib-0043","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009281","article-title":"Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction","volume":"15","author":"Zylla","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0044","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehad620","article-title":"Surgical pericardiotomy to treat heart failure with preserved ejection fraction: A first clinical study","volume":"44","author":"Borlaug","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804194524000_ehf215401-bib-0045","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"2026021804194524000_ehf215401-bib-0046","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.122.059486","article-title":"Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure","volume":"145","author":"Borlaug","year":"2022","journal-title":"Circulation"},{"key":"2026021804194524000_ehf215401-bib-0047","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jchf.2024.04.011","article-title":"2-year outcomes of an atrial shunt device in HFpEF\/HFmrEF: Results from REDUCE LAP-HF II","volume":"12","author":"Gustafsson","year":"2024","journal-title":"J Am Coll Cardiol HF"},{"key":"2026021804194524000_ehf215401-bib-0048","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jamacardio.2024.0520","article-title":"Atrial shunt device effects on cardiac structure and function in heart failure with preserved ejection fraction: The REDUCE LAP-HF II randomized clinical trial","volume":"9","author":"Patel","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0049","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cardfail.2012.06.530","article-title":"Hemodynamic determinants of the abnormal cardiopulmonary exercise response in heart failure with preserved left ventricular ejection fraction","volume":"18","author":"Maeder","year":"2012","journal-title":"J Card Fail"},{"key":"2026021804194524000_ehf215401-bib-0050","first-page":"177","article-title":"Masked left ventricular restriction in elderly patients with atrial septal defects: A contraindication for closure?","volume":"52","author":"Ewert","year":"2001","journal-title":"Cathet Cardiovasc Intervent"},{"key":"2026021804194524000_ehf215401-bib-0051","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0052","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40472-015-0075-4","article-title":"Current treatment strategies in pulmonary hypertension associated with left heart disease","volume":"2","author":"Selby","year":"2015","journal-title":"Curr Transpl Rep"},{"key":"2026021804194524000_ehf215401-bib-0053","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10154-1","article-title":"Can mechanical circulatory support be an effective treatment for HFpEF patients?","author":"Gude","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026021804194524000_ehf215401-bib-0054","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026021804194524000_ehf215401-bib-0055","first-page":"4626","volume-title":"2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society [Internet]","author":"Lovett","year":"2009"},{"key":"2026021804194524000_ehf215401-bib-0056","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1161\/CIRCHEARTFAILURE.109.877720","article-title":"Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction","volume":"3","author":"Phan","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0057","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.2196","article-title":"Splanchnic nerve modulation in heart failure: Mechanistic overview, initial clinical experience, and safety considerations","volume":"23","author":"Fudim","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0058","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/07853890.2021.1905873","article-title":"Catheter ablation superiority over the pharmacological treatments in atrial fibrillation: A dedicated review","volume":"53","author":"Alrumayh","year":"2021","journal-title":"Ann Med"},{"key":"2026021804194524000_ehf215401-bib-0059","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10741-024-10456-0","article-title":"The sympathetic nervous system in heart failure with preserved ejection fraction","volume":"30","author":"Chang","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026021804194524000_ehf215401-bib-0060","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1097\/00005344-198608005-00008","article-title":"Mechanism of elevated plasma noradrenaline in the course of essential hypertension","volume":"8","author":"Esler","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026021804194524000_ehf215401-bib-0061","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jchf.2019.03.021","article-title":"The role of the pericardium in heart failure: Implications for pathophysiology and treatment","volume":"7","author":"Borlaug","year":"2019","journal-title":"J Am Coll Cardiol HF"},{"key":"2026021804194524000_ehf215401-bib-0062","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ejhf.2144","article-title":"Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction","volume":"23","author":"Woolley","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804194524000_ehf215401-bib-0063","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042220-022745","article-title":"Heart failure with preserved ejection fraction: Mechanisms and treatment strategies","volume":"73","author":"Omote","year":"2022","journal-title":"Annu Rev Med"},{"key":"2026021804194524000_ehf215401-bib-0064","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009594","article-title":"Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure risk score: Validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction","volume":"7","author":"Rich","year":"2018","journal-title":"JAHA"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3878\/66968167\/eschf_12_6_3878.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3878\/66968167\/eschf_12_6_3878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:19:52Z","timestamp":1771406392000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/3878\/8488195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,8,26]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15401","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"2025-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}